PHAT (Phathom Pharmaceuticals, Inc.) Stock Financials & Earnings

PHATPhathom Pharmaceuticals, Inc.

Mkt Cap$891M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$175M

Net Income (TTM)-$221M

EPS (TTM)-$3.06

Free Cash Flow (TTM)-$167M

Gross Margin87.1%

Op. Margin-91.4%

Net Margin-126.3%

FCF Margin-95.2%

P/S Ratio (TTM)5.1x

P/E Ratio (TTM)—

YoY Rev Growth+216.9%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$30M
Q2 23	$0	-$123K	-$32M
Q3 23	$0	-$121K	-$36M
Q4 23	$682K	$330K	-$70M
Q1 24	$2M	$1M	-$70M
Q2 24	$7M	$6M	-$77M
Q3 24	$16M	$14M	-$71M
Q4 24	$30M	$26M	-$59M
Q1 25	$29M	$25M	-$79M
Q2 25	$40M	$34M	-$60M
Q3 25	$50M	$43M	-$15M
Q4 25	$58M	$50M	-$6M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$11M	$19M	—
Q2 23	$13M	$19M	—
Q3 23	$12M	—	$23M
Q4 23	$13M	—	$57M
Q1 24	$9M	—	$62M
Q2 24	$7M	$76M	—
Q3 24	$9M	—	$76M
Q4 24	$9M	—	$77M
Q1 25	$9M	—	$94M
Q2 25	$9M	—	$85M
Q3 25	$7M	—	$52M
Q4 25	$7M	—	$48M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$130M	$0	$130M
Q2 23	$249M	$0	$249M
Q3 23	$214M	$0	$214M
Q4 23	$381M	$0	$381M
Q1 24	$322M	$0	$322M
Q2 24	$276M	$0	$276M
Q3 24	$335M	$0	$335M
Q4 24	$297M	$0	$297M
Q1 25	$212M	$0	$212M
Q2 25	$150M	$0	$150M
Q3 25	$135M	$0	$135M
Q4 25	$130M	$0	$130M

Shares Outstanding

Revenue Per Employee

Revenue / Employee